1. Extraordinary Cases in VTE

2. Patient Case

3. Guideline Recommendations Treatment and Secondary Prophylaxis of Cancer-Associated VTE

4. 2018 NCCN Guidelines for Cancer-Associated VTE

5. Patient Characteristics to Consider when Selecting NOAC vs LMWH

6. LMWH and Chemotherapy-Induced Thrombocytopenia

7. Hokusai-VTE Cancer − Study Design

8. HOKUSAI-VTE Cancer Primary Outcome First Recurrent VTE or Major Bleeding Event

9. Drop in Platelet Count Insights from the Hokusai-VTE Cancer Trial

10. SELECT-D Dalteparin vs Rivaroxaban in Patients with Cancer

11. Sites of Major Bleeding

12. Hokusai-VTE Cancer Secondary Outcomes

13. GI Cancer and Major Bleeding

14. US Prescription Patterns for Cancer-Associated VTE

15. Potential Anticancer and NOAC Drug Interactions

16. Take-Home Messages

17. Abbreviations